General form of registration statement for all companies including face-amount certificate companies

Commitments and Contingencies (Details)

v2.4.0.8
Commitments and Contingencies (Details) (USD $)
6 Months Ended 12 Months Ended
Jun. 30, 2013
Dec. 31, 2012
Abbott Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]
   
Summary of milestone payment    
Milestones payments $ 750,000 $ 750,000
Abbott Biotherapeutics Corp [Member] | Phase II Clinical Trial of a licensed product [Member]
   
Summary of milestone payment    
Milestones payments 750,000 750,000
Abbott Biotherapeutics Corp [Member] | Phase III Clinical Trial of a licensed product [Member]
   
Summary of milestone payment    
Milestones payments 1,500,000 1,500,000
Abbott Biotherapeutics Corp [Member] | Biological License Application filing with U.S. FDA [Member]
   
Summary of milestone payment    
Milestones payments 1,750,000 1,750,000
Abbott Biotherapeutics Corp [Member] | First Commercial Sale [Member]
   
Summary of milestone payment    
Milestones payments 1,500,000 1,500,000
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member]
   
Summary of milestone payment    
Milestones payments 1,500,000 1,500,000
Memorial Sloan Kettering Cancer Center [Member] | New Drug Application [Member]
   
Summary of milestone payment    
Milestones payments 750,000 750,000
Memorial Sloan Kettering Cancer Center [Member] | Receipt of Regulatory Approval From U.S. FDA [Member]
   
Summary of milestone payment    
Milestones payments $ 1,750,000 $ 1,750,000